Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	1,982	1,887	1,489	1,134	1,046	788.1
Revenue Growth (YoY)	23.99%	26.76%	31.34%	8.38%	32.71%	74.67%
Cost of Revenue	38.7	39.7	23.2	14.3	10.1	7.4
Gross Profit	1,943	1,847	1,466	1,119	1,036	780.7
Selling, General & Admin	888	887.6	752.7	583.3	433.3	354.1
Research & Development	584.9	565	463.8	328.1	275	200
Other Operating Expenses	6	143.9	0	105.3	164.5	154.3
Operating Expenses	1,479	1,597	1,217	1,017	872.8	708.4
Operating Income	464.4	250.9	249	102.5	163	72.3
Interest Expense / Income	4.6	4.6	7.1	25.8	32.8	32
Other Expense / Income	-10.1	-85.8	28	-24.7	23.5	-6.2
Pretax Income	469.9	332.1	213.9	101.4	106.7	46.5
Income Tax	100.2	82.4	59.4	11.8	-300.6	9.5
Net Income	369.7	249.7	154.5	89.6	407.3	37
Net Income Growth	477.66%	61.62%	72.43%	-78.00%	1000.81%	75.36%
Shares Outstanding (Basic)	100	98	96	95	93	92
Shares Outstanding (Diluted)	104	101	99	98	98	96
Shares Change	6.69%	2.12%	1.02%	0.10%	2.19%	0.31%
EPS (Basic)	3.77	2.56	1.61	0.95	4.38	0.40
EPS (Diluted)	3.65	2.47	1.56	0.92	4.16	0.39
EPS Growth	498.36%	58.33%	69.57%	-77.88%	966.67%	77.27%
Free Cash Flow	614.4	361.6	322.9	233.1	217.6	132.3
Free Cash Flow Per Share	6.16	3.70	3.37	2.46	2.34	1.44
Gross Margin	98.05%	97.90%	98.44%	98.74%	99.03%	99.06%
Operating Margin	23.43%	13.30%	16.73%	9.04%	15.58%	9.17%
Profit Margin	18.65%	13.23%	10.38%	7.90%	38.94%	4.69%
Free Cash Flow Margin	31.00%	19.16%	21.69%	20.56%	20.81%	16.79%
Effective Tax Rate	21.32%	24.81%	27.77%	11.64%	-281.72%	20.43%
EBITDA	497	358	236.6	138.1	148.1	85.9
EBITDA Margin	25.08%	18.97%	15.89%	12.18%	14.16%	10.90%
Depreciation & Amortization	22.5	21.3	15.6	10.9	8.6	7.4
EBIT	474.5	336.7	221	127.2	139.5	78.5
EBIT Margin	23.94%	17.84%	14.85%	11.22%	13.34%	9.96%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).